100757-92-4

Upstream product

• 201230-82-2 carbon monoxide 
• 589-87-7 1,4-bromoiodobenzene 
• 100-99-2 triisobutylaluminum 
• 5674-02-2 2-methylpropylmagnesium chloride 
• 1122-91-4 4-bromo-benzaldehyde 
• 106-37-6 1.4-dibromobenzene 
• 590-86-3 isovaleraldehyde 
• 926-62-5 isobutylmagnesium bromide 

Downstream Products

• 1393126-57-2 (+/-)-methyl 3-(4-(3-methyl-1-(4-(4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)butoxy)benzamido)propanoate 
• 1393126-56-1 (+/-)-4-(3-methyl-1-(4-(4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)butoxy)benzoic acid 
• 1393126-55-0 (+/-)-methyl 4-(3-methyl-1-(4-(4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)butoxy)benzoate 
• 1393122-57-0 (+/-)-3-(4-(3-methyl-1-(4-(4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)butoxy)benzamido)propanoic acid 
• 1393125-46-6 (+/-)-methyl 4-(1-(4-bromophenyl)-3-methylbutoxy)benzoate 
• 103857-71-2 1-bromo-4-isopentylbenzene 

Relevant academic research and scientific papers

Benzobis(thiadiazole) derivative and organic electronics device comprising same

A benzobis(thiadiazole) derivative represented by the formula (1): in which R represents a group containing at least one fluorine atom (with the proviso that fluorine atom (F) and trifluoromethyl group (—CF3) are excluded), and m represents an integer of from 1 to 10.

BENZOBIS(THIADIAZOLE) DERIVATIVE AND ORGANIC ELECTRONICS DEVICE USING SAME

The present invention relates to a benzobis(thiadiazole) derivative represented by the formula (1): wherein R represents a group containing at least one fluorine atom (with the proviso that fluorine atom (F) and trifluoromethyl group (-CF3) are excluded), and m represents an integer of from 1 to 10.

Modulators of methyl modifying enzymes, compositions and uses thereof

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein

GLUCAGON RECEPTOR MODULATORS

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Thiophenesulfonamides as endothelin receptor antagonists

The synthesis and in vitro binding affinities of a series of thiophenesulfonamides as ET(A) selective endothelin receptor antagonists is described. The most potent inhibitor displayed an IC50 of 43 nM and 3 μM to ET(A) and ET(B) receptors, respectively.

CARBONYLATIVE CROSS-COUPLING REACTION OF ARYL IODIDES WITH ALKYLALUMINUMS BY PALLADIUM COMPLEX CATALYSIS

Secondary and/or tertiary alcohols and unsymmetrical ketones have been obtained in moderate to good yields by palladium-catalyzed (5 molpercent) carbonylative coupling of aryl iodides with alkylaluminum compounds under very mild conditions (20-50 deg C, 1 atm of carbon monoxide).The type of th reaction product depended on the aluminum reagent employed.While the selective formation of secondary alcohols was observed in the reaction with i-Bu3Al, the use of Et3Al led to a mixture of a ketone and two alcoholic products.With Et2AlCl predominantly unsymmetrical ketones were produced.In all cases, formation of directly cross-coupled products was not observed.DME and benzene can be used as solvents, but THF is unsuitable.Nickel catalysts were found to be ineffective for this reaction.